Roche Diagnostics has introduced a new procedure to detect antigens associated with Hepatitis B, to aid in diagnosis. The recently released immunoassay is intended to detect antigens in blood and plasma specimens.
This test not only identifies the antigen’s presence but also calculates the volume of antigens. This feature aids in assessing the severity of a patient’s condition and evaluating their response to treatment.
Furthermore, Roche states it can be employed in conjunction with other hepatitis B diagnostics to identify the stage of the disease, monitor the impact of the virus on the liver, and assess the likelihood of progression to liver cancer.
Leading executive of Roche Diagnostics, Matt Sause, stressed, “Hepatitis B affects millions of people each year and is a major global health burden. An accurate diagnosis is critical to ensuring timely treatment options.”
Sause went on to add, “The addition of the Elecsys HBeAg quant immunoassay to our viral hepatitis testing portfolio underlines Roche’s commitment to tackle healthcare’s biggest challenges to support clinicians and their patients.”
© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.